Similar Items: Vascular cognitive impairment and dementia drug‐development pipeline 2025
- Currently Available Biomarkers and Strategies for the Validation of Novel Candidates for Neurochemical Dementia Diagnostics in Alzheimer’s Disease and Mild Cognitive Impairment
- Alzheimer's disease drug development pipeline: 2026
- Druggable genome‐wide Mendelian randomization analysis identifies potential treatment targets in vascular dementia
- Testing Van Gool’s Hypothesis: A Method to Predict Side Effects of Cholinesterase Inhibitors in Patients with Cellular Degenerative and Vascular Dementia
- Refining cognitive dispersion metrics for brain–behavior prediction in aging and mild cognitive impairment
- A potential multimodal biomarker – cognitive signature associated with the conversion from subjective cognitive decline to mild cognitive impairment